Rapport Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| For the three months ended September 30, | For the nine months endedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses | ||||
| Research and development (1) | $15,543 | $7,580 | $43,736 | $16,200 |
| General and administrative (2) | 6,097 | 1,984 | 15,798 | 5,185 |
| Total operating expenses | 21,640 | 9,564 | 59,534 | 21,385 |
| Loss from operations | (21,640) | (9,564) | (59,534) | (21,385) |
| Other income (expense): | ||||
| Interest income | 4,103 | 856 | 8,597 | 1,152 |
| Change in fair value of preferred stock tranche right liability | — | — | (7,390) | (1,030) |
| Total other income, net | 4,103 | 856 | 1,207 | 122 |
| Net loss before income taxes | (17,537) | (8,708) | (58,327) | (21,263) |
| Provision for income taxes | — | 1 | — | 4 |
| Net loss | $(17,537) | $(8,709) | $(58,327) | $(21,267) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.50) | $(5.70) | $(3.66) | $(14.72) |
| Weighted-average common shares outstanding, basic and diluted | 34,855,907 | 1,529,216 | 15,925,777 | 1,444,666 |
| Comprehensive loss: | ||||
| Net loss | $(17,537) | $(8,709) | $(58,327) | $(21,267) |
| Change in unrealized gains (losses) on investments, net of tax | 583 | — | 396 | — |
| Total other comprehensive income (loss) | 583 | — | 396 | — |
| Comprehensive loss | $(16,954) | $(8,709) | $(57,931) | $(21,267) |
(1)
Includes related party amounts ofzero for each of thethree months ended September 30, 2024 and 2023, and less than $0.1 million and $0.5 million for thenine months ended September 30, 2024 and 2023, respectively (see Note 10).
(2)
Includes related party amounts ofzero and $0.2 million for thethree months ended September 30, 2024 and 2023, respectively and $0.1 million and $0.7 million for thenine months ended September 30, 2024 and 2023, respectively (see Note 10).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.